Biblio

Author Title [ Type

] Year

Filters: Author is Bhojwani, Deepa [Clear All Filters]

Journal Article

Verma A, Chi Y-Y, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li H-T, Liang G, Leong R, Brown PA, et al. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers (Basel). 2024;16(3).

Winestone LE, Bhojwani D, Ghorashian S, Muffly L, Leahy ABarz, Chao K, Steineck A, Rossig C, Lamble A, Maude SL, et al. INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2023.

Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, Inaba H, Bhojwani D, Metzger ML, Cheng C, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2014.

Burke A, Vinti L, Kabickova E, Beishuizen A, Tacyildiz N, Uyttebroeck A, Kang HJin, Luisi F, Minard-Colin V, Burkhardt B, et al. Ibrutinib plus RICE/RVICI for R/R mature B-NHL in children/young adults: SPARKLE trial. Blood Adv. 2022.

Hasle H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, Bhojwani D, Verboon JM, DiTroia SP, Chao KR, Raaschou-Jensen K, Palle J, et al. Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood. 2021.

Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi Y-Y, Sposto R, et al. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022.